Introduction {#Sec1}
============

Genomic studies have revealed that late-onset Alzheimer disease (LOAD) is highly polygenic, with as many as 30 susceptibility loci identified through large-scale meta-analysis of genome-wide association studies (GWAS), targeted exome genotyping array, and several early whole exome sequencing (WES) studies \[[@CR1]--[@CR12]\]. Although AD susceptibility is highly heritable (*h*^*2*^ = 0.58--0.79) \[[@CR13]\], much of its genetic architecture is still unknown and few rare variants have been detected thus far \[[@CR3], [@CR6], [@CR7], [@CR14]--[@CR19]\]. Discovery of rare variants in genomic studies, even those with large sample sizes and examining highly heritable diseases, remains challenging due to statistical power limitations in detecting all but the most strongly associated variants (odds ratio (OR) \> 1.5) \[[@CR20]--[@CR23]\]. The protein coding regions of the genome, or exome, are the best characterized and most conserved portions of the genome and the source of most variants identified to date that are responsible for Mendelian diseases \[[@CR24]\]; thus, the exome is a more attractive and less expensive target for identifying rare variants of large effect on disease than the non-protein coding portion of the genome.

The Alzheimer's Disease Sequencing Project (ADSP) was developed jointly by the National Institute on Aging (NIA) and National Human Genome Research Institute (NHGRI) in response to the National Alzheimer's Project Act milestones (<https://aspe.hhs.gov/national-alzheimers-project-act>) to fight Alzheimer's disease (AD) as an effort to analyze the genomes of well-characterized individuals with and without AD. To detect rare variants and genes associated with LOAD, we performed single-variant and gene-based analyses, including annotated loss-of-function analyses, on the ADSP Discovery Phase Case-Control WES dataset, and attempted to replicate associations in three independent WES datasets, a GWAS dataset containing single nucleotide variants (SNVs) that were imputed using the Haplotype Reference Consortium (HRC) \[[@CR25]\] reference panel, and the ADSP family-based whole genome sequence dataset.

Methods {#Sec2}
=======

Sample selection and data preparation {#Sec3}
-------------------------------------

Study participants were either European-American (EA) or Caribbean Hispanic (CH) ancestry and were sampled in two ways. To maximize contrast between cases and controls, and power to discover novel associations, the majority of participants were chosen using a risk score that included dosages of the *APOE* ε2/ε3/ε4 alleles, sex and either onset age (for cases) or age at last exam for controls (or pathology-based adjusted age at death for neuropathology control) \[[@CR26]\]. All cases were at least 60 years old and met NINCDS-ADRDA criteria for possible, probable or definite AD based on clinical assessment, or had presence of AD (moderate or high likelihood) upon neuropathology examination. To maximize our ability to discover novel genetic associations, we chose cases whose AD risk score indicated that their disease was not well explained by age, sex, or dosages of the *APOE* ε2/ε3/ε4 alleles. Conversely, cognitively healthy controls were selected with the goal of identifying alleles associated with the increased risk of or protection from late-onset AD. At the time of last exam, all potential controls were at least 60 years old and were either judged to be cognitively normal or did not meet pathological criteria \[[@CR27], [@CR28]\] for AD following brain autopsy. Controls were selected for this study on the basis of the risk score indicating that they were the least likely to develop AD by age 85 years. Applying the risk score resulted in a sample that contained 2,220 AD cases (40%) and 752 controls (14%) who were ε4 heterozygotes and 161 AD cases (3%) and 17 controls (\<1%) who were ε4 homozygotes.

In addition, we sampled a set of "enriched" cases from families having at least three affected members for whom the diagnosis of AD was verified by direct examination or review of cognitive testing data and medical records. Cases from early-onset AD families or families with a known *PSEN1*, *PSEN2*, or *APP* mutation were excluded. Within each family, we selected only one AD case, typically the member with the lowest *a priori* AD risk (based on the risk score defined above), provided this person had sufficient genomic DNA. In addition, because 172 of the "enriched" cases described above were of CH ancestry, we also selected a set of 171 age- and sex-matched cognitively normal CH participants to serve as controls. Participant characteristics are shown in Table [1A](#Tab1){ref-type="table"}.Table 1Participant CharacteristicsA. Discovery SampleAD Cases (N = 5,740)Cognitively Normal Controls (N = 5,096)AncestrySamplingNAge (mean)Sex (%F)APOE E4 (%carrier)NAge (mean)Sex (%F)APOE E4 (%carrier)EACase-Control5,01575.2555.8%40.6%4,91986.5359.2%14.4%EAEnriched50783.6163.3%66.9%NANANANAHispanicCase-Control4672.5971.7%43.5%685.9466.7%16.7%HispanicEnriched17275.4561.6%39.5%17173.4660.8%39.2%B. Replication SampleAD Cases (N = 12,121)Cognitively Normal Controls (N = 18,789)NAge (mean)Sex (% F)APOE ε4 (% carrier)NAge (mean)Sex (% F)APOE ε4 (% carrier)CHARGEWES6128167%54%1,8368058%24%ADES-FRWES1,1427464%49%1,1048058%22%FinnADWES1,0247462%\--4,3227151%\--ADGCGWAS9,3437454%64%11,5277554%25%

Procedures {#Sec4}
==========

Genotype calling and data processing {#Sec5}
------------------------------------

WES data were generated at the Broad Institute, the Baylor College of Medicine's Human Genome Sequencing Center, and Washington University's McDonnell Genome Institute. An effort was made to assign all samples from a study of origin to the same center and there was a relatively balanced number of cases and controls at each center. Genotypes for bi-allelic SNVs and insertion-deletion polymorphisms (indels) were called using ATLAS2 using version Ch37/hg19 of the reference genome. A coordinated effort was implemented for centralized variant calling and quality control (QC) efforts in order to create one batch of data for analysis. Although there were differences in allele frequencies across sequencing centers for some variants, it was difficult to determine whether these represented technical artifacts of different capture kits, variability in genetic background among cohorts assembled for this study, or chance differences that will often occur for infrequent or rare variants. QC steps and methods for evaluating cryptic relatedness, population substructure, differential missingness, and variant annotation are described in the [Supplementary Materials](#MOESM1){ref-type="media"}.

Single-variant and gene-based association analyses {#Sec6}
--------------------------------------------------

### Statistical models & rationale for covariate adjustments {#Sec7}

All models included adjustment for sequencing center and population substructure. Before conducting the primary analyses, we evaluated up to 20 PCs for association with AD status. Only ancestry-specific PCs that significantly associated with AD status (*P*\<0.005) in at least one of the three adjustment models were included as covariates (EA subgroup: PC1, PC5, PC8, PC9, PC10, PC11, PC18; Hispanic analyses included PC1 and PC2). Because most participants for the discovery study were sampled to maximize differences in cases and controls based on age, sex, and *APOE* genotypes, we included only PCs and sequencing center in our base adjustment model (Model 0). We evaluated two other models that included several covariates in addition to those in the base model: Model 1 adjusted for sex and age at diagnosis or last follow-up; and Model 2 adjusted for *APOE* ε4 & ε2 dosages in addition to those included in Model 1. All analyses were performed separately by ancestry (EA and CH) using seqMeta (version 1.6) \[[@CR29]\]; the primary analysis is an inverse variance-weighted meta-analysis of these two groups. Single variant tests were limited to variants with at least 10 copies of the minor allele across the total QCed sample (MAF\~0.0005).

### Gene-based association testing {#Sec8}

Gene-based tests examine the aggregate effect of risk and protective variants within a region defined by gene annotations. We performed gene-based tests using SKAT-O, which optimally combines SKAT and burden tests \[[@CR30]\]. For these analyses, the SKAT portion of the test included variants with a MAF≤0.05; the burden component aggregated variants with MAF≤0.01. The SKAT test used 'Wu weights', defined by a beta density function with pre-specified parameters a1 = 1 and a2 = 25, evaluated at the sample minor allele frequency. The SKAT-O statistic, a linear combination between a SKAT statistic (Q~skat~) and a burden statistic (Q~burden~) equal to (1-ρ) Q~skat~ + ρQ~burden~, was optimized across 11 values of ρ (0.1 increments), and calculation of the significance took into consideration the multiple values of ρ evaluated. In order to improve power by removing variants predicted to have a low functional impact on the translated protein, we filtered variants in each gene on the basis of annotated function as described in the [Supplementary Materials](#MOESM1){ref-type="media"}. We performed SKAT-O testing for genes with at least two qualifying variants contributing to the test. The minimum number of aggregated alleles (i.e., cumulative minor allele count or cMAC) for a gene-based test was set at 10.

### Statistical significance thresholds for discovery stage analyses {#Sec9}

Within each analysis framework including individual variants and gene-based aggregation of variants evaluated under particular functional annotation criteria, suggestive associations (p \< 1/ \# tests) were selected for follow-up testing in independent samples and a Bonferroni-corrected threshold was used to define experiment wide statistical significance (p \< 0.05 / \# tests). We did not correct for the three models and meta-analyses of the combined results of the EA + CH populations because the results were highly correlated across the covariate adjustment strategies (Supplementary Figure [S2](#MOESM1){ref-type="media"}).

### Replication sample and analyses {#Sec10}

Primary replication analyses for the SNVs / genes that we identified to be genome-wide significant or suggestive in any model were conducted in three independent WES datasets including CHARGE (612 cases and 1,836 controls), ADES-FR (1,142 cases and 1,104 controls) \[[@CR31]\], and FinnAD (1,024 cases and 4,322 controls), as well as in the Alzheimer's Disease Genetics Consortium (ADGC) HRC-imputed GWAS dataset (Table [1B](#Tab1){ref-type="table"}, [Supplementary Materials](#MOESM1){ref-type="media"}, Supplementary Table [S1](#MOESM1){ref-type="media"}). The ADGC dataset included GWAS data on 9,343 cases and 11,527 cognitively normal elders from 32 datasets for whom genotypes were imputed using the Haplotype Reference Consortium (HRC) r1.1 reference panel (Supplementary Table [S2](#MOESM1){ref-type="media"}) \[[@CR25], [@CR32]\]. CHARGE and ADGC participants selected for ADSP discovery analyses were not included in the replication study.

Because we included all available cases and controls in the replication datasets instead of applying the participant selection criteria used for the discovery sample to maximize difference in cases and controls, model 0 is not appropriate in replication studies. Hence, single variant tests and gene-based SKAT-O tests were performed using seqMeta for models 1 and 2 only. Meta-analysis of summarized results from the four samples was performed using seqMeta. We also performed a meta-analysis of results across the ADSP discovery and four replication cohorts for findings that were at least "suggestive" (p \< 1 / genes or variants) in the discovery phase. In addition to models 1 and 2, we conducted a meta-analysis of results obtained using model 0 in the ADSP discovery data and model 1 in the replication cohorts to verify our findings in ADSP model 0. Because the ADSP discovery dataset includes CH participants and all replication cohorts consist of EA participants only, we performed the meta-analysis with and without CH participants in ADSP. We considered any variants or genes with two-stage meta-analysis p-values \< 0.05 / \# tests to be significant per the recommendation by Skol et al. that joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies \[[@CR33]\]. We acknowledge, however, that additional replication in independent samples is required.

The top findings in the discovery sample were also followed-up in the ADSP whole-genome sequenced (WGS) family-based dataset \[[@CR34], [@CR35]\]. This dataset includes 197 individuals sequenced in 42 EA families and 351 individuals in 67 CH families. Additional follow-up was also performed using WGS information from 150 members of another 48 CH families. Individual variants were assessed by examining their co-segregation with AD status within families. Gene-based association tests were performed using the FSKAT software \[[@CR36]\].

### Analysis of variants at previously established AD loci {#Sec11}

To identify a set of variants related to AD risk in loci previously associated with AD, we compiled a list of genes containing variants with significant or suggestive associations (p \< 1 × 10^−3^) in either the published IGAP or UKBB AD GWAS meta-analyses \[[@CR9], [@CR37]\]. Because many signal variants from GWAS are in intergenic regions, we used a combination of BEDOPS \[[@CR38]\] and BEDTools \[[@CR39]\] operations to enlarge the genomic coordinates of these associated variants by 50 Kb on each side, merging adjacent regions that were overlapping and/or book-ended. Of the resulting genomic regions, segments greater than 100 kb were retained, shortened by 50 kb on each side, merged if separated by 200 kb or less, and utilized to find overlapping protein-coding genes, with gene boundaries as defined in version 19 of the GENCODE gene set \[[@CR40]\] and a 50 kb buffer on each side. These parameters and sequence of operations were chosen because they resulted in an algorithm that satisfactorily captured the genomic interval of the association landscape at each locus, as confirmed by visual inspection of LocusZoom regional plots \[[@CR41]\]. We queried variant and gene level association statistics for the resulting list of 299 putatively associated AD genes.

Results {#Sec12}
=======

Description of study samples after QC and filtering {#Sec13}
---------------------------------------------------

After exclusions, 10,836 participants were available for analysis (5,740 cases; 5,096 controls). This included 218 CH cases and 177 CH controls. The study included more women than men, and, due largely to the selection criteria, cases were younger on average than controls and were more likely to carry one copy of the *APOE* ε4 allele. In total, the data included 1,524,414 bi-allelic SNVs or short indels. Most variants were rare, with 1,493,926 (98%) of variants having minor allele frequency of less than 5% and 160,898 (11%) having a minor allele count (MAC) of at least 10 copies.

Single-variant SNV and short indels association analysis {#Sec14}
--------------------------------------------------------

We performed single variant analyses for the 160,898 variants with a combined minor allele count of at least 10 copies across all participants (Supplementary Figure [S3](#MOESM1){ref-type="media"}). Genomic inflation was moderate (λ \< 1.1 in all models) (Supplementary Figures [S4](#MOESM1){ref-type="media"}--[S7](#MOESM1){ref-type="media"}). Single variant association testing identified three variants at an exome-wide significance level (p \< 3.1 × 10^−7^) and 14 variants at the suggestive threshold (p \< 6.1 × 10^−6^) outside of the *APOE* region (Table [2](#Tab2){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}, Supplementary Table [S3](#MOESM2){ref-type="media"}). The significant associations included the rare missense R47H variant in *TREM2* (rs75932628, p = 4.8 × 10^−12^), a common variant in *PILRA* (rs2405442, p = 1.7 × 10^−7^), and a novel rare variant in the long non-coding RNA *AC099552.4* (7:154,988,675, p = 1.2 × 10^−7^). These results were attenuated when including age, sex, and *APOE* ε2/ε3/ε4 allele as covariates.Table 2Associations with Individual Variants outside the *APOE* regionADSP Discovery MetaAll Replication (ADGC+CHARGE+ADES-FR+FinnAD)Discovery + All ReplicationNamegeneMAC (EA/CH)best PModel (group)MACP Model 1P Model 2P Model 0P Model 1P Model 26:41129252:C:T (R47H)TREM2120/0**4.8E-12**0 (EA)224**1.6E-062.7E-063.2E-162.8E-101.6E-10**7:154988675:G:AAC099552.410/0**1.2E-07**2 (EA)0NANA*1.3E-02****2.0E-07**1.2E-07***7:99971313:T:C (rs2405442)PILRA6,219/219**1.7E-07**0 (EA)22,7985.3E-052.3E-05**9.5E-10**1.1E-065.0E-0720:62729814:C:T (rs148484121)OPRL161/45.8E-071 (all)1113.4E-015.6E-013.7E-031.4E-044.5E-0411:59940599:T:A (rs7232)MS4A6A7,540/2587.7E-070 (all)20,963**1.4E-113.1E-095.6E-173.8E-142.6E-11**17:44828931:G:A (rs199533)NSF4,238/1351.3E-060 (all)11,1202.5E-011.4E-022.1E-041.6E-021.9E-0414:106235767:C:T (rs77307099)IGHG36,200/1761.9E-060 (all)7214.0E-013.5E-01**1.4E-06**1.3E-047.9E-0514:106235766:G:A (rs78376194)IGHG36,202/1761.9E-060 (all)7194.2E-013.6E-01**1.5E-06**1.4E-048.5E-056:15638035:C:T (rs77460377)DTNBP116/31.9E-062 (all)358.5E-018.7E-018.7E-025.2E-033.0E-036:33041297:G:A (rs112178281)HLA-DPA110/02.9E-061 (EA)67.5E-019.2E-011.4E-012.1E-052.0E-0511:59945745:T:C (rs12453)MS4A6A8,265/2583.2E-060 (EA)23,420**4.7E-113.0E-081.4E-156.0E-131.2E-09**3:195506101:T:AMUC438/63.8E-061 (all)0NANA*3.0E-043.8E-068.1E-06*10:88446985:T:C (rs76615432)LDB3760/625.0E-061 (CH)2,3035.3E-015.9E-017.0E-016.3E-016.4E-0119:1047507:AGGAGCAG:AABCA767/04.3E-060 (EA)118.8E-029.7E-022.4E-041.6E-021.7E-0214:106236128:T:A (rs12890612)IGHG36,395/3694.5E-060 (all)1,4738.5E-027.5E-02**9.8E-07**8.0E-056.4E-057:99799845:T:A (rs104395)STAG35,248/2485.5E-060 (EA)15,9483.0E-031.2E-03**8.8E-07**1.2E-044.0E-05Table shows variants with *P* \< 6.1 × 10^−6^ in EA, CH^,^ or combined strata in the discovery sample. Exome-wide significant results (*P* \< 3.1 × 10^−7^) and suggestive results which improved in meta analysis of discovery + replication data are highlighted in bold. Results without variation data in the replication datasets are indicated in *italics*Fig. 1Manhattan plot showing genome-wide association results for individual common variants. The plot shows the p-values from the Discovery meta-analysis against their genomic position for association with AD. Only variants with a combined minor allele count of ≥ 10 were included; the minimum p-value from the three adjustment models for either the meta-analysis, European Ancestry (EA), or Caribbean Hispanic (CH) is plotted for each variant. Genes containing the variant are indicated above points that surpassed our significance threshold for follow-up. The dotted line indicates the threshold for follow-up, p \< 6.1 × 10^−6^, corresponding to (1 / \#variants) tested. The dashed line indicates the threshold for exome-wide significance, p \< 3.1 × 10^−7^, corresponding to (0.05 / \#variants tested)

Gene-based association analysis combining SNVs and indels {#Sec15}
---------------------------------------------------------

We aggregated 918,053 variants with a combined MAF \< 0.05 and annotated as high or moderate impact into gene-based tests using SKAT-O. This corresponds to 17,613 genes with more than one variant and a cumulative minor allele count (cMAC) of at least 10 copies. Applying more stringent filtering, we limited to variants annotated as high impact; aggregating 42,502 rare or uncommon (MAF \< 0.05) variants into 4,634 genes (again, limiting to genes with \>1 variant and a cMAC ≥ 10). For the purposes of identifying novel associations, we considered all genes or variants within 250kb of *APOE* as part of the *APOE l*ocus. Three known genes (*ABCA7*, *TREM2* and *CBLC* in the *APOE* region) and two novel genes (*OPRL1* and *GAS2L2*) achieved exome-wide statistical significance for their respective tests in the discovery analyses (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). Four additional genes (*ZNF655*, *RHBDD1*, *SIRPB1*, and *RPS16*) reached suggestive significance across the nine models (Fig. [2](#Fig2){ref-type="fig"}, Supplementary Table [S4](#MOESM2){ref-type="media"}). Analyses filtered to include only variants with CADD scores ≥ 15 or ≥ 20 produced most of the same top-ranked results as the VEP gene-based results (Supplementary Table [S5](#MOESM2){ref-type="media"}), noting that the overall VEP High/Moderate and CADD≥15 results, as well as the VEP High and CADD≥20 results, are only moderately correlated (Spearman rank correlation r = 0.51) (Supplementary Figure [S8](#MOESM1){ref-type="media"}). Three novel genes (*CACNB3, HHIP-AS1*, and *RP11-68L1.1*) were exome-wide statistically significant in the CH group in analyses restricted to variants with CADD scores ≥ 20 (Supplementary Table [S5](#MOESM2){ref-type="media"}), however these are likely false positives because in each instance the result is accounted for by a single variant that was observed in one person only.Table 3Gene-based Association ResultsADSP Discovery MetaAll ReplicationDiscovery + All ReplicationGeneVariants bSNVsbest PModelSNVsP Model 1P Model 2SNVsP Model 0P Model 1P Model 2TREM2High-Mod50**1.8E-11**033**9.3E-105.4E-09**65**2.0E-173.8E-116.0E-11**CBLC ^a^High-Mod44**1.1E-07**035**2.5E-206.7E-03**61**1.0E-276.1E-22**4.9E-02OPRL1High-Mod42**2.6E-06**1371.3E-013.0E-01648.3E-035.4E-041.7E-03CBX3High-Mod86.0E-050101.3E-012.8E-01174.9E-044.6E-026.1E-02BCAM ^a^High-Mod905.2E-04188**4.7E-19**3.7E-03144**3.5E-272.8E-20**4.8E-02GAS2L2High7**3.9E-06**255.1E-026.7E-02104.5E-013.9E-022.9E-02ZNF655High92.8E-05063.2E-023.4E-0213**7.9E-06**8.4E-043.4E-04RHBDD1High23.2E-05248.8E-019.8E-0153.5E-014.8E-012.7E-01SIRPB1High68.0E-05239.2E-017.9E-0186.4E-013.0E-012.6E-01RPS16High51.6E-04227.4E-014.2E-0154.4E-027.7E-036.5E-03ABCA7LoF43**2.1E-06**0161.5E-011.1E-01511.2E-041.2E-033.4E-04GAS2L2LoF7**3.9E-06**233.9E-024.8E-0285.2E-014.3E-022.5E-02ZNF655LoF81.9E-05043.9E-023.0E-0210**5.0E-06**4.6E-042.0E-04RPS16LoF31.6E-04227.4E-014.2E-0134.1E-027.9E-036.4E-03Table shows genes with *P*-value \< 5.7 × 10^−5^ (High-Mod^)^, 2.2 × 10^−4^ (High), or 2.8 × 10^−4^ (LoF) in the total discovery sample. Results surpassing discovery stage Bonferroni corrected significance thresholds \-- *P* = 2.8 × 10^−6^ (High-Mod^),^ 1.1 × 10^−5^ (High), and 1.4 × 10^−5^ (LoF) -- are indicated in bold.^a^located in *APOE* region^b^type of functional variants included in gene-based testFig. 2Manhattan plots showing exome-wide association results for gene-based tests of rare functional variants. The plots show the gene-based p-values from the Discovery meta-analysis against their genomic position for association with AD. Each point represents a p-value from SKAT-O test aggregating rare variants (MAF \< 5%), by gene, on the basis of predicted functional impact. Only genes with a cumulative minor allele count of ≥ 10 were included; the minimum p-value from the three adjustment models for either the meta-analysis, European Ancestry (EA), or Caribbean Hispanic (CH) is plotted for each variant. Genes are indicated above points that surpassed our significance threshold for follow-up in tests aggregating only (**a**) moderate or high impact variants, (**b**) high impact variants; (**c**) loss-of-function variants. In each plot, the dotted line indicates the threshold for follow-up: (**a**) p\<5.5 × 10^−5^, (**b**) p\<6.3 × 10^−5^, (**c**) p\<2.8 × 10^−4^, each corresponding to 1 / \# genes tested. The dashed line indicates the threshold for exome-wide significance: (**a**) p\<2.7 × 10^−6^, (**b**) p\<3.1 × 10^−6^, (**c**) p \< 1.4 × 10^−5^, each corresponding to 0.05 / \# genes tested

Loss-of-function (LOF) association analysis {#Sec16}
-------------------------------------------

Among 78,529 unfiltered high impact variants, 72,694 were annotated as LoF and 68,121 were further deemed as high-confidence, most of which were frameshift and stop-gained (Fig. [3](#Fig3){ref-type="fig"}). As expected, over 90% of these high-confidence LoF variants were singletons (53,120, 78%), doubletons (6,579, 10%), or tripletons (2,222, 3%), and most of these were observed in European Americans only. Association analysis of 2,378 high-confidence LoF variants with MAC ≥ 10 with adjustment for sequencing center and PCs revealed one Bonferroni corrected significant p \< 2.1 × 10^−5^) variant, a previously reported frameshift deletion in *ABCA7* (Table [3](#Tab3){ref-type="table"}) \[[@CR42]\]. Gene-based analysis of 32,863 high-confidence LoF variants with MAF ≤ 5% mapping to 3,558 genes with at least two variants and cMAC ≥ 10 (Supplementary Table [S4](#MOESM2){ref-type="media"}) also showed that *ABCA7* with adjustment for sequencing center and PCs (Model 0) and *GAS2L2* with adjustment for sequencing center, PCs, sex, age, and *APOE* genotype (Model 2) reached experiment-wide significance threshold p \< 1.4 × 10^−5^).Fig. 3Distribution of high impact, LoF and high-confidence LoF variants grouped by predicted consequence

Replication analysis {#Sec17}
--------------------

Of the 16 single variants outside the *APOE* region tested in the replication samples (Table [2](#Tab2){ref-type="table"}, Supplementary Table [S3](#MOESM2){ref-type="media"}), the *TREM2* R47H mutation and four variants in three other previously known genes (one missense and one synonymous variant in *MS4A6A*, a synonymous variant in *PILRA*, and a missense variant in *CR1*) were significantly associated with AD in the combined discovery and replication analysis (Table [2](#Tab2){ref-type="table"}). Associations with two variants in a novel gene *STAG3* (rs1043915, p = 5.5 × 10^−6^) were also replicated and significantly associated with AD. We were unable to assess replication with the novel *AC099552.4* variant because it was not observed or imputed in the replication datasets. One of the *IGHG3* variants (rs12890621) showed borderline evidence for association in models 1 and 2 (p = 0.085 and 0.075, respectively), and evidence for association was strengthened to near exome-wide significance (p = 9.8 × 10^−7^) in the combined discovery and replication sample.

In total, 19 genes across the nine models were significantly or suggestively associated with AD and were tested in the replication stage (Supplementary Table [S4](#MOESM2){ref-type="media"}). Gene-based tests including high or moderate impact variants showed evidence for replication and reached genome-wide significance in the combined discovery and replication analysis for three genes:*TREM2* and two genes in the *APOE* region (*CBLC* and *BCAM*) (Table [3](#Tab3){ref-type="table"}, Supplementary Table [S6](#MOESM2){ref-type="media"}). The association with *GAS2L2*, the potential novel gene identified in a model 2 SKAT-O test with high impact SNVs in the discovery sample, was slightly above the nominal significance level (p = 0.051 and p = 0.067, respectively, in models 1 and 2) in meta-analysis across four replication cohorts. However, this association was only nominally significant in the meta-analysis combining the discovery and replication cohorts (p = 0.029 for model 2).

In gene-based tests including only high impact SNVs, the known AD risk gene *ABCA7* and the potential novel gene *ZNF655* reached the nominal p-value of 0.05 in meta-analysis with replication cohorts as well as in a meta-analysis of discovery and replication samples (Table [3](#Tab3){ref-type="table"}, Supplementary Table [S6](#MOESM2){ref-type="media"}). These two genes were also nominally significant in SKAT-O tests, limited to high impact variants (*ZNF655*: p = 7.9 × 10^−6^; *ABCA7*: p = 6.2 × 10^−5^) and LOF variants (*ZNF655*: p = 5.0 × 10^−6^).

Because *PILRA*, a previously established AD gene \[[@CR43]\] is proximate to *STAG3* (159 kb) and *ZNF655* (797 kb), we performed conditional analysis in the discovery sample to determine whether these novel association signals are independent. These analyses demonstrated that the association with multiple rare variants *ZNF655* in the gene-based test is distinct from those with common variants in *PILRA* (p = 1.08 × 10^−4^) and *STAG3* (p = 7.75 × 10^−5^). In a model containing both *PILRA* and *STAG3* variants the association with *PILRA* remains significant (p = 0.011) but the association with *STAG3* does not (p = 0.21) (Supplementary Table [S7](#MOESM2){ref-type="media"}).

Follow-up in ADSP family-based data {#Sec18}
-----------------------------------

We also followed-up the significant and suggestive single-variant and gene-based results from the discovery stage in the ADSP whole-genome sequenced (WGS) family-based dataset. A rare missense variant (rs61756195, MAF = 0.001) in *STAG3* segregated with disease in three CH families and trended toward association in the case-control study (p = 0.052) **(**Supplementary Table [S8](#MOESM2){ref-type="media"}). Gene-based testing identified a nominal association for *GAS2L2* (p = 0.049) in EA families (Supplementary Table [S9](#MOESM2){ref-type="media"}).

Rare variants in established genes from GWAS {#Sec19}
--------------------------------------------

We interrogated our individual variant and gene-based aggregate association tests for 299 previously associated AD genes. Among the SNVs and indels, a total of 1,172 variants with MAF \< 0.05 and annotated as either HIGH or MODERATE impact are located within 253 interrogated AD genes (Supplementary Table [S10](#MOESM2){ref-type="media"}). Five of these variants were at least suggestively significant (p\<8.9 × 10^−4^) in single variant testing. The most significant associations included the *TREM2* R47H missense mutation (p = 4.8 × 10^−12^) and *ABCA7* frameshift mutation E709fs (p = 4.3 × 10^−6^) which was previously associated with AD in Belgian families \[[@CR40]\]. Additional notable signals included variants in *SORL1* A528T (p = 8.7 × 10^−5^), which was previously associated with AD in a CH population \[[@CR15]\], and *ACP2* D353E (p = 7.8 × 10^−4^). Perturbation of murine *Acp2* causes lysosomal storage deficits, kyphoscoliosis, cerebellar abnormalities, and ataxia \[[@CR44], [@CR45]\].

For gene-based tests, we aggregated variants on the basis of annotated function, and examined only genes with more than one contributing variant and a cMAC ≥ 10. Of the 299 AD genes, tests were performed on 281 genes aggregating high or moderate impact variants and 86 genes limited to high impact variants. Among these, 13 unique genes surpassed suggestive significance thresholds for high (p \< 1.16 × 10^−2^)orhigh-moderate (p = 3.56 × 10^−3^) impact variants. The strongest associations were observed for moderate impact variants in *TREM2* (p = 4.81 × 10^−12^) and *SORL1* (p = 8.68 × 10^−5^), and a high impact variant in *ABCA7* (p = 4.33 × 10^−6^). Other noteworthy signals included moderate impact variants in *NUP88* (p = 4.63 × 10^−4^) and *ACP2* (p = 7.80 × 10^−4^).

Discussion {#Sec20}
==========

Our WES study, the largest for AD conducted to date, identified novel associations with variants in three genes not previously implicated in AD including one common nearly exome-wide significant variant each in *IGHG3* (p = 9.8 × 10^−7^) and *STAG3* (p = 8.8 × 10^−7^), and one rare exome-wide significant variant in *AC099552.4* (p = 1.2 × 10^−7^). We also observed a gene-wide significant association with *ZNF655* in a gene-based test including nine high-impact rare variants (p = 5.0 × 10^−6^). These results remained significant after multiple test correction and were confirmed in or strengthened by a replication sample comprised of four independent datasets, with the exception of the variant in *AC099552.4* which was invariant in the replication samples. We also confirmed associations with common and rare variants in several previously established AD genes including *ABCA7, APOE, HLA-DPA1, MS4A6A, PILRA, SORL1* and *TREM2*.

*ZNF655* is expressed in brain and encodes the Vav-interacting Krüppel-like factor 1 \[[@CR46]\]. Krüppel-like factors (KLFs) are zinc finger-containing transcription factors that regulate diverse biological processes, including proliferation, differentiation, growth, development, survival, and responses to external stress \[[@CR47]\]. Several KLFs have been shown to participate in neuronal morphogenesis and to control the regenerative capacity of neurons in the central nervous system. *AC099552.4* is a long non-coding RNA, an abundant class of RNA sequences which regulate gene transcription and expression \[[@CR48]\] and impact neuronal development, neuroplasticity, and cognition \[[@CR49]\]. Non-coding RNA-dependent regulation affecting AD-related processes has been demonstrated for *SORL1* \[[@CR50]\] and in a triple transgenic model of AD \[[@CR51]\].

*IGHG3* encodes immunoglobulin heavy constant gamma 3 and is a member of the IgG family for which antibodies have been shown to cross-react with fibril and oligomer amyloid-β aggregates \[[@CR52]\] leading to speculation that Immunoglobulin GM (γ marker) genes contain functional risk and protective factors for AD \[[@CR53]\]. The anti-amyloidogenic activity of IgG appears to be an inherent property of free human IgG heavy chains \[[@CR54]\]. Recent analysis of structural variants in whole genome sequence data for 578 members of 101 families with multiple AD subjects included in the ADSP \[[@CR26]\] yielded additional evidence supporting *IGHG3* as an AD risk locus. A total of nine distinct deletions in the *IGH* region were identified as disproportionately represented in AD cases compared to controls. One of these is a 188 bp deletion that was observed in 35 AD cases and 8 controls and is located 592 bp from the AD-associated SNV (rs12890621) in this study. This deletion eliminates a large portion of *IGHG3* intron 2 and exon 3 (reference transcript ENST00000390551), and is predicted to have high impact on the encoded product. It is unlikely that the deletion and rs12890621 tag the same effector of AD risk because the deletion is rare, whereas rs12890621 is more common (MAF = 0.0475 in EA subjects according to the ExAC database). Of note, a nearby pseudogene in the IgG family, *IGHV1-67*, located approximately 350 kb from *IGHG3*, has been previously reported in a gene-wide association study conducted by the International Genetics of Alzheimer's Project (IGAP) \[[@CR1]\].

The association with the common synonymous variant in *STAG3* (rs1043915, MAF = 0.26) is not independent of the finding with a common SNV in *PILRA*, a previously reported AD-associated gene \[[@CR43]\] located in an established AD locus \[[@CR9]\]. However, rare variants in *STAG3* identified by WGS showed evidence of co-segregation with AD in CH families suggesting the possibility that *STAG3* has a distinct mechanistic role in AD. *STAG3*, stromal antigen 3, encodes a subunit of the cohesin complex which regulates the cohesion of sister chromatids during cell division. Whether the association with AD observed here is mediated at least in part through *STAG3* function or simply reflects linkage disequilibrium with other causal variants/genes in the region remains to be established. Rare coding *STAG3* variants have been identified in primary ovarian insufficiency \[[@CR55]\]. Although *STAG3* is expressed in the brain, its role remains unclear. Interestingly, data from GTEx show that the associated variant is an eQTL for multiple genes in various brain tissues, including *STAG3, AGFG2, GAL3ST4, GATS*, and *PVRIG*. In a mouse model of diabetes, microvascular damage in the neurovascular unit of the retina was associated with alteration in *STAG3* expression \[[@CR56]\].

A variant in *NSF* showed nominally significant evidence of association in the replication sample (p = 0.014) in the model adjusting for age, sex, and *APOE* ε4 status, whereas the result in the discovery sample was observed in the model without these covariates. *NSF* encodes N-ethylmaleimide sensitive factor, vesicle fusing ATPase is involved in membrane trafficking of proteins and neurotransmitter release \[[@CR57]\], and has been observed in brain homogenates of cases of familial neuronal intranuclear inclusion disease \[[@CR58]\]. *NSF* SNVs have been associated with cocaine dependence \[[@CR59]\] and its expression is reduced in prefrontal cortex in schizophrenia patients \[[@CR60]\]. Vesicular trafficking has an important role in AD exemplified by genetic and biological evidence for neuronal sorting proteins including *SORL1* \[[@CR61]--[@CR63]\].

We were unable to replicate variants at five loci that showed significant association in the discovery sample (p ≤ 5.0 × 10^−6^). Failure to replicate findings for the *OPRL1* and *DTNBP1* variants may be due to their lower MAF and, hence, uncertainty in the imputation quality and lack of imputed indels in the ADGC GWAS replication sample. Nonetheless, both of these genes are potentially attractive biological candidates. Opioid related nociceptin receptor 1 modulates a variety of biological functions and neurobehavior, including learning and memory, and inflammatory and immune functions \[[@CR64], [@CR65]\]. *DTNBP1* encodes the dystrobrevin binding protein 1 which has been genetically linked to multiple psychiatric disorders, as well as cognitive and memory functions in healthy human subjects \[[@CR66], [@CR67]\].

Analysis of rare variants in the regions of genes previously identified as related to AD by GWAS revealed genome-wide significant or suggestive evidence of association in established genes including *TREM2, SORL1*, and *ABCA7*. In addition, notable associations were observed with other genes in these regions not previously linked to AD including *TREML4, SPPL2A*, and *AP4M1* (Supplementary Table [S10](#MOESM2){ref-type="media"}). *TREML4* is located near *TREM2* and encodes a *TREM* family receptor that, similar to *TREM2*, is expressed on the surface of myeloid cells and participates in the phagocytic clearance of dead cells \[[@CR68]\]. *SPPL2A* encodes an endosomal-lysosomal protease and presenilin homolog that regulates B-cell homeostasis *in vivo* \[[@CR69]\]. Homozygous mutations in *AP4M1*, located in the region including *PILRA* and *STAG3*, cause spastic tetraplegia, intellectual disability, and white matter loss \[[@CR70]\]. Its encoded protein is a component of the AP-4 trafficking complex that regulates APP processing and beta-amyloid secretion in cell models \[[@CR71]\]. Further studies are needed to conclude whether the association findings in this latter group of genes are robust and warrant experiments to determine their functional relevance to AD.

Notably, there is little overlap of our results with findings of large GWAS focused on common variants \[[@CR1], [@CR2], [@CR9]\]. This is due in part to our focus on only infrequent or rare variants (MAF \< 0.05) that are functionally-annotated to be of at least moderate impact and may not have been well covered by GWAS arrays or imputation. With the notable exception of *APOE*, common variants associated with AD have very modest effect on risk (OR \< 1.3) \[[@CR9]\], and all but a few of these associations \[[@CR4], [@CR5], [@CR8], [@CR10], [@CR12]\] required a sample between two and nearly seven times larger than the sample in this study to have sufficient power to detect them \[[@CR1], [@CR2], [@CR9]\].

Our study has several notable strengths and limitations. The ascertainment scheme for this sample is optimal for detection of association with both risk and protective variants for AD \[[@CR26]\]. Specifically, the AD cases were selected to have relatively early onset (with a minimum age of 65) and a lower frequency of the *APOE* ε4 allele with the expectation that they were likely to be more enriched for rare high-penetrant AD risk-variants compared to most late-onset AD cases. Controls were selected to be as old as possible with preference given to those having at least one *APOE* ε4 allele to enrich this group for protective variants. However, this scheme introduced confounding between age and AD status which reduced power for detecting associations. To overcome this limitation, we included a model without age adjustment which yielded the largest number of new association findings including several that were replicated in independent datasets which were analyzed with age adjustment. Thus, it was important to include models which did or did not include a covariate for age in order to account for confounding with AD status as well as age-dependent effects of the genetic factor. Despite simulations showing that this sample had sufficient power to detect associations with variants whose frequencies were as low as 0.005 and an effect size greater than 1.8 \[[@CR26]\], the number of novel rare variant findings were few. We also acknowledge that p-value thresholds did not account for the number of models tested, however the models are highly correlated (Supplementary Table [S2](#MOESM1){ref-type="media"}**)**.

The inclusion of CH participants who were a pivotal portion of a multi-ethnic sample leading to the discovery of common variant associations in other AD loci, most notably *SORL1* \[[@CR62]\], but for rare variant discovery these samples may have reduced power by increasing genetic heterogeneity of the total sample. This conclusion is consistent with observations of few novel findings in this WES study showing discernable contributions by the CH dataset and by discovery of novel rare variant associations in a whole genome sequence study that were unique to EA and CH families, respectively \[[@CR34], [@CR35]\]. Nonetheless, the non-Hispanic portion of our sample was sufficiently large to detect multiple novel associations. Our findings suggest that additional large and ancestrally diverse cohorts with deep sequence data will need to be examined for replication and to provide a larger discovery sample.

Successful replication of only some of the most significant findings in novel genes not in the *APOE* region (4/8 individual variants in Table [2](#Tab2){ref-type="table"}, 1/18 genes in Table [3](#Tab3){ref-type="table"}) is somewhat concerning but highlights the difficulty of designing well-powered replication studies of sequencing findings. Although it is possible that some of these findings are false positives, we acknowledge that the size of the WES replication samples combined (2,778 AD cases, 7,262 controls) was inadequate. In addition, many rare variants were not well-imputed or, in the case of most indels, not imputed at all in the ADGC GWAS dataset, despite the use of the HRC reference panel which contains haplotypes derived from whole genome sequence data for more than 30,000 individuals who were not ascertained for AD research. Thus, additional large WES samples will need to be studied to obtain definitive evidence about findings that did not replicate.

In summary, our significant association findings with functional rare variants in novel genes provide further support for the roles of neuroinflammation (*IGHG3*) and transcriptional regulation (*AC099552.4* and *ZNF655*) in AD. In addition, we identified many novel associations with rare functional variants in previously established AD genes. In most cases, these rare variants do not explain association signals that were previously identified by GWAS with common and predominantly non-functional variants. Hence, many of our findings will provide insight into disease mechanisms and targets for biological experiments to gain further understanding about the role of these genes in AD pathogenesis. However, other deep sequencing approaches (e.g., whole genome, target gene resequencing) will be needed to identify variants which account for association signals in non-coding regions and the contribution of structural variants (e.g., larger insertions and deletions, copy number variants, etc.) to AD risk.
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